Gland Pharma
Other · 12 quarters tracked · source-linked performance and management context.
Latest revenue
₹1,742.8 Cr
verified financial record
Quarters tracked
12
source records in the directory
Delivery assessment
0
Across 13 tracked commitments: 0 delivered, 13 missed.
Call date
2026-05-15
latest available source date
Signal trajectory
12 actual quartersCurrent read
0/100
Across 13 tracked commitments: 0 delivered, 13 missed.
Latest source read
What changed this quarter?
Gland Pharma reported a strong Q4 FY26 with consolidated revenue of INR 17,428 million (+22% YoY) and adjusted EBITDA margin of 30% (+500bps YoY), driven by robust CDMO growth (28% YoY), new product launches (dalbavancin, multivitamin), and improved Cenexi performance (EBITDA positive). Base business EBITDA margin was 41%. Management guided for 12-13% constant currency revenue growth in FY27 (ex-GLP-1), with CDMO contributing INR 40-50 million incremental revenue. Cenexi targets mid-single to high-single digit EBITDA margin in FY27 and mid-teen in medium term. Risks include Middle East conflict impact on ROW business and potential glass/solvent cost inflation of 1-2%.
Colored figures compare against the previous available record. Hover or focus one for the comparison.
Signal
Positive
Revenue
₹1,742.8 Cr
Source date
2026-05-15
Across the record
Quarter history.
History modules